Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: KEGG:D01817 (Iohexol)
 504 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effects on urine and serum profiles of intravenous injection of diatrizoate, iohexol, or saline were studied in male rats pretreated with steroids or saline. Using urinary albumin, glucose, sodium, and the enzymes lactate dehydrogenase (LDH), gamma-glutamyltransferase (GGT), and N-acetyl-beta-D-glucosaminidase (NAG) as markers of glomerular and tubular function, it was found that diatrizoate caused temporary glomerular and tubular dysfunction; the effect was independent of the kind of pretreatment. Iohexol did not cause increased glomerular permeability in steroid- and saline-pretreated rats. When used following saline, iohexol induced increased excretion of three tubular components, whereas iohexol plus steroids caused increased excretion of all five tubular components. The dysfunctional effect of iohexol plus steroids was less than that of diatrizoate plus steroids. The serum components revealed no abnormalities induced by either contrast media or methylprednisolone. Pretreatment with steroids has no effect on the glomerular or tubular dysfunctional effect of diatrizoate, whereas it worsens the temporary tubular dysfunctional effect of iohexol in rats.
Invest Radiol 1991 Dec
PMID:Pretreatment with steroids before intravenous injection of diatrizoate or iohexol. Effects on urine and serum profiles. 176 42

The incidence of adverse reactions following standard film or screen cervical myelography with iohexol in 32 adult outpatients was reported. Iohexol at a dose of 1,080-3,000 mg of iodine was administered via a lateral C1-C2 approach in 26 patients and via a lumbar route in 6 patients. All 32 patients underwent postmyelographic cervical spine computed tomography and were discharged after the procedure was completed. No adverse reactions occurred in 53.1% of patients. The most common adverse reaction was headache (31.3%); other minor adverse reactions included exacerbation of pre-existing pain (12.5%), neck stiffness (9.4%), and vomiting (6.3%). Good to excellent technical quality was seen on all myelograms and computed tomographic scans. Outpatient cervical myelography with iohexol appears to be a safe and cost-effective alternative to inpatient examination.
Spine (Phila Pa 1976) 1991 Dec
PMID:Iohexol cervical myelography in adult outpatients. 177 64

Dacryocystography has been widely used in the assessment of the nasolacrimal duct system, particularly in patients with epiphora. Our study was undertaken to evaluate image quality and level of patient discomfort during examinations with water-soluble contrast agents (iohexol [Omnipaque 240], iopamidol [Isovue 200 and 300], and 52.7% diatrizoate meglumine and 26.9% iodipamide meglumine [Sinografin]) compared with the iodized oil-based contrast agent Lipiodol. Fifty-five dacryocystograms were obtained from 41 consecutive patients. The procedure was performed first with a water-soluble contrast agent, then repeated with Lipiodol. A distention technique was used with conventional radiography. Patients were asked to evaluate their level of discomfort (none, mild, moderate, severe). The images were evaluated separately by two radiologists, blinded to which water-soluble agent was employed, and the images were graded on a five-point scale. Images obtained with Lipiodol were significantly better than those with other agents (P less than .02), and image quality deteriorated as iodine concentration decreased. Use of Isovue 300 and Sinografin produced significantly more patient discomfort (P less than .03) than the use of other agents. The authors conclude that, in most instances, Lipiodol is the contrast agent of choice with regard to both highest level of patient comfort and greatest conventional radiographic image quality among the agents compared.
Radiology 1989 Dec
PMID:Dacryocystography: comparison of water-soluble and oil-based contrast agents. 255 62

Decreasing or alleviating pain experienced by some patients during or after temporomandibular arthrography would make this relatively inexpensive and highly accurate technique more attractive. This is particularly true for those patients without access to MR or those whose referring physicians prefer arthrography to other techniques for diagnosing internal derangements. Ionic and nonionic contrast agents were compared in a randomized, double-blind trial to determine if pain could be decreased by using a nonionic contrast material. Forty patients received either Omnipaque 300 (nonionic, iohexol) or Hypaque 60 (ionic, diatrizoate meglumine). Radiographs were assessed for diagnostic quality, and patients were asked to note their level of discomfort. No significant differences between the agents were detected. Maximal discomfort was noted at 24 hr. Discomfort was classified as none, mild, or moderate, with no patients describing marked discomfort. This study does not support the use of nonionic contrast agents over the less expensive ionic agents for decreasing pain or improving film quality in temporomandibular joint arthrography.
AJR Am J Roentgenol 1989 Dec
PMID:Comparison of omnipaque with hypaque in temporomandibular arthrography. 281 36

Blood that contaminates the contrast agent syringe during angiography may clot and is thus a potential source of emboli. The older, high-osmolality agents prevent clotting. Newer, low-osmolality agents, while possessing other advantages, are less effective in this regard. The time over which such mixtures do not contain clot can be determined by allowing gross clotting to take place, modeling the process mathematically and determining the clot-free time from the model. Blood-contaminated Omnipaque-300 (Winthrop-Breon, New York, NY) (iohexol), Isovue-300 (E.R. Squibb and Sons, New Brunswick, NJ) (iopamidol), Hexabrix (Mallinckrodt, St. Louis, MO) (ioxaglate sodium meglumine), Renografin-76 (E.R. Squibb and Sons, New Brunswick, NJ) (diatrizoate sodium meglumine), and saline were studied in glass and plastic syringes (80 samples of each agent). After deliberate blood contamination, Renografin and Hexabrix showed no clots during the 90-minute study period. There was, however, a 1.3% chance of clotting in Omnipaque (range 0.4%-4.0%) and a 1.9% chance of clotting in Isovue (range 0.6%-5.5%) at 5 minutes after contamination of these contrast agents in plastic syringes. The chance of clotting in glass containers was significantly greater. We conclude that Hexabrix is a substantially stronger anticoagulant than Omnipaque and Isovue. Furthermore, it appears that this method will allow determination of clotting risks for other combinations of contrast agent and container.
Invest Radiol 1988 Dec
PMID:A technique for estimating the probability of clots in blood/contrast agent mixtures. 320 94

We present a method for the quantification of the contrast agent iohexol in serum. Iohexol is deiodinated by alkaline hydrolysis and the released iodine subsequently measured according to the ceric arsenite method. The assay requires 50 microliters of serum and has a high capacity as it involves few analytical steps. The high precision (2% CV) and sensitivity make the method applicable to the recently developed procedure for the determination of glomerular filtration rate, which is based on the assessment of the clearance of iohexol from serum. The method is simple and rapid and requires no expensive equipment.
Scand J Clin Lab Invest 1988 Dec
PMID:A simple chemical method for the quantification of the contrast agent iohexol, applicable to glomerular filtration rate measurements. 323 27

Iohexol and iopamidol, two new nonionic contrast media, have been extensively studied in comparison with metrizamide for lumbar myelography. Review of the literature with statistical analysis indicates both agents are superior to metrizamide in terms of number of patients with adverse reactions (p less than 0.001). Preliminary data suggest, but do not prove, that use of iohexol may result in fewer side effects than iopamidol.
Surg Neurol 1986 Dec
PMID:Tolerance of iohexol, iopamidol, and metrizamide in lumbar myelography. 377 30

A multicenter clinical study was conducted using iohexol, a second-generation nonionic contrast medium, for excretory urography performed in 130 children. Doses of iohexol (300 mg iodine/ml) ranged between 150 and 660 mgI/kg (0.5 and 2.2 ml/kg). Iohexol was tolerated well, and no significant adverse reactions occurred. Sixty-five iohexol urograms were evaluated to determine the minimum dose for adequate visualization of the kidneys and collecting systems. A dose greater than 300 mgI/kg (1.0 ml/kg) always resulted in a urogram of diagnostic quality, while visualization was insufficient for diagnosis in 10% of studies done with doses of 150-300 mgI/kg (0.5-1.0 ml/kg). Another 65 iohexol urograms were compared in a blinded manner with a similar number of studies performed using iothalamate meglumine at comparable iodine concentration and dose. Visualization of calyces and pelvoinfundibular structures achieved with iohexol was rated better with statistical significance, but there was no difference in visualization of the renal parenchyma or ureters. Use of iohexol in excretory urography may be advantageous in children who are at greatest risk for an adverse reaction to contrast media or in those most likely to benefit from use of a low osmolality contrast agent.
Radiology 1986 Dec
PMID:Excretory urography with iohexol: evaluation in children. 378 8

Two hundred and twenty-five patients investigated by left ventricular, coronary artery and/or proximal aortic angiography were randomly assigned to one of three contrast medium groups (Hexabrix 320, Niopam 300 or Omnipaque 300). Subjective response to injection of contrast medium was noted at the time of investigation and during the next 24 h. No significant difference was found between the three currently available low-osmolar contrast media.
Br J Radiol 1985 Dec
PMID:Comparison of low-osmolar contrast media in cardiac angiography. 384 28

The contrast enhancement of low-osmolality (iohexol) and high-osmolality (diatrizoate) contrast media was compared in 18 pigs following intravenous bolus administration. Liver and blood attenuation and blood sample iodine concentration were measured during the first 3 minutes after injection. Iohexol produced a significantly higher contrast enhancement in the blood during the period from 0.5 to 3 minutes after injection. Diatrizoate produced a significantly higher contrast enhancement in the liver during the period from 9 to 30 minutes after injection. The greater contrast enhancement of iohexol during the acute phase should be advantageous in dynamic CT.
Invest Radiol 1985 Dec
PMID:Contrast enhancement of the liver and blood. Nonionic versus ionic contrast media in the pig. 407 51


1 2 Next >>